Needham & Company LLC Reaffirms Buy Rating for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ:NBIX)‘s stock had its “buy” rating restated by stock analysts at Needham & Company LLC in a research note issued to investors on Monday,Benzinga reports. They presently have a $185.00 target price on the stock. Needham & Company LLC’s target price indicates a potential upside of 41.33% from the stock’s current price.

Several other equities research analysts have also commented on NBIX. Wolfe Research initiated coverage on shares of Neurocrine Biosciences in a report on Tuesday, February 24th. They issued an “outperform” rating and a $160.00 price target for the company. Royal Bank Of Canada reduced their price target on shares of Neurocrine Biosciences from $180.00 to $177.00 and set an “outperform” rating for the company in a report on Thursday, February 12th. Wall Street Zen lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Monday, February 16th. Wedbush boosted their price target on shares of Neurocrine Biosciences from $149.00 to $151.00 and gave the company an “outperform” rating in a report on Thursday, February 12th. Finally, Mizuho boosted their price target on shares of Neurocrine Biosciences from $146.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, December 12th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $180.70.

Neurocrine Biosciences Price Performance

Neurocrine Biosciences stock opened at $130.90 on Monday. The stock has a market cap of $13.14 billion, a price-to-earnings ratio of 28.09, a price-to-earnings-growth ratio of 0.69 and a beta of 0.35. Neurocrine Biosciences has a 1 year low of $84.23 and a 1 year high of $160.18. The firm has a 50-day moving average of $131.46 and a two-hundred day moving average of $138.91.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Wednesday, February 11th. The company reported $1.88 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.36 by ($0.48). The company had revenue of $805.50 million during the quarter, compared to analysts’ expectations of $804.21 million. Neurocrine Biosciences had a net margin of 16.73% and a return on equity of 16.48%. Neurocrine Biosciences’s quarterly revenue was up 28.3% on a year-over-year basis. During the same period last year, the firm earned $1.69 earnings per share. Research analysts expect that Neurocrine Biosciences will post 4.28 earnings per share for the current year.

Insider Activity at Neurocrine Biosciences

In related news, CEO Kyle Gano sold 36,400 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $132.70, for a total transaction of $4,830,280.00. Following the completion of the transaction, the chief executive officer owned 140,407 shares in the company, valued at $18,632,008.90. The trade was a 20.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 4.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. USA Financial Formulas bought a new position in shares of Neurocrine Biosciences during the 4th quarter worth approximately $25,000. Golden State Wealth Management LLC raised its stake in shares of Neurocrine Biosciences by 120.5% during the 3rd quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock worth $26,000 after acquiring an additional 100 shares in the last quarter. Eastern Bank bought a new position in shares of Neurocrine Biosciences during the 3rd quarter worth approximately $27,000. DJE Kapital AG bought a new position in shares of Neurocrine Biosciences during the 4th quarter worth approximately $28,000. Finally, Geneos Wealth Management Inc. raised its stake in shares of Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after acquiring an additional 135 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Key Stories Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Acquisition materially expands Neurocrine’s commercial footprint — adds VYKAT XR (first‑and‑only FDA‑approved therapy for hyperphagia in Prader‑Willi syndrome) and pushes the company into endocrinology/rare metabolic diseases, creating a multi‑product commercial platform alongside INGREZZA and CRENESSITY. Neurocrine Grows in Endocrinology, Rare Disease with $2.9B Soleno Buyout
• Positive Sentiment: Analysts reacted by lifting price targets and reiterating buys — multiple firms (Citigroup, Canaccord, HC Wainwright, BofA, Needham, Wedbush) raised targets substantially, signaling upside to consensus estimates and investor confidence in the deal’s revenue potential. Vykat XR Acquisition Unlocks Diversified Growth — TipRanks
• Neutral Sentiment: Market validated Soleno’s value — SLNO shares jumped sharply on the deal, confirming the premium paid by Neurocrine and market willingness to pay for VYKAT XR’s orphan indication. This supports deal rationale but doesn’t guarantee NBIX near‑term earnings upside. Soleno Therapeutics Soars 32% on $2.9B Merger
• Neutral Sentiment: Soleno voluntarily withdrew its European marketing application for VYKAT XR ahead of the takeover — Neurocrine says it will prioritize the U.S. launch. That could accelerate U.S. commercialization focus but delays/forgoes near‑term EU revenue. Soleno withdraws EU rare disease drug application — Reuters
• Negative Sentiment: Shares dropped on deal announcement — investors appear concerned about the price tag ($2.9B cash), near‑term dilution to capital flexibility or execution risks integrating a new therapeutic area while Neurocrine’s pipeline faces a near‑term lull. This immediate negative reaction drove today’s decline. This Pharma Stock Is Surging 40% — Barron’s
• Negative Sentiment: Some analysts caution on execution and orphan market risks — at least one firm (BMO) kept a Hold, highlighting integration and long‑term execution questions that could cap near‑term multiple expansion. Balanced View on Neurocrine — TipRanks

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.